Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Recruiting 3Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6

Conditions

Ovarian Neoplasms 10Breast Neoplasms 6Triple Negative Breast Neoplasms 3Sarcoma 3Fallopian Tube Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Cancer Metastatic 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1SCLC, Extensive Stage 1Recurrence 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Fludzoparib" and Anti-angiogenic 1Female Breast Cancer Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × fluzoparib × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07353437 2026-01-20

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

Fudan University

Phase 2 Not yet recruiting
334 enrolled
Breast

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Fudan University

Phase 2 Recruiting
620 enrolled
Breast

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

Fudan University

Phase 2 Not yet recruiting
260 enrolled
Breast

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Fudan University

Phase 3 Recruiting
766 enrolled
Breast

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown
319 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡